Email bulletins

Archive

August 2017

  • World Hepatitis Day: steps towards elimination
  • Drug prices: time to shift from talking about high prices to low production costs
  • Hepatitis C: DAA treatment and mortality
  • Vosevi approved in the European Union and United States
  • Maviret approved in the European Union and United States
  • Epclusa use expanded to people with HIV co-infection in the United States
  • Harvoni licence extended to adolescents aged 12-18 years in European Union
  • Hepatitis C treatment in Africa
  • Non-alcoholic fatty liver disease in people living with HIV
  • Is this your copy of the infohep news bulletin?

June 2017

  • Cochrane review of hepatitis C treatment strongly criticised
  • New pangenotypic drug combinations
  • Recent infection with hepatitis C and testing for hepatitis C
  • Sofosbuvir treatment for adolescents and children
  • US monitoring and surveillance recommendations
  • Coming soon: IAS 2017
  • Is this your copy of the infohep news bulletin?

May 2017

  • New hepatitis C infections in the United States
  • HCV reinfection among people who inject drugs
  • Gilead warning on generics – weeks after more evidence on effectiveness
  • Albumin treatment in decompensated cirrhosis
  • New drugs for hepatitis B treatment
  • Is this your copy of the infohep news bulletin?

April 2017

  • News from the 2017 International Liver Congress
  • WHO Global Hepatitis Report 2017
  • New hepatitis B clinical guidelines from EASL
  • HCV reimbursement criteria in Europe
  • Direct-acting antivirals and liver cancer risk
  • Hepatitis C treatment for children
  • AbbVie combination
  • HCV treatment reduces cardiovascular risk
  • Parkinson’s disease and hepatitis
  • Statins reduce the risk of decompensation
  • Antibiotic prophylaxis reduces mortality in decompensated cirrhosis
  • Coming soon: HR17
  • Is this your copy of the infohep news bulletin?

April 2017

  • Progress towards elimination of hepatitis C
  • Global Burden of Disease study shows viral hepatitis causes more deaths than HIV or TB
  • Debate: Not all drug preparation equipment may contain infectious HCV
  • Women who inject drugs at greater risk of HCV
  • Nivolumab (Opdivo) approved for hepatocellular carcinoma treatment in the United States
  • Janssen halts hepatitis C drug research
  • Next month: news coverage of The Liver Meeting 2017
  • Is this your copy of the infohep news bulletin?

March 2017

  • Early treatment for hepatitis C
  • Access to hepatitis C treatment in South East Asia
  • Cancers
  • Liver cancer and treatment for viral hepatitis
  • Direct-acting antiviral treatment achieves high cure rates in the most advanced liver disease patients with HIV co-infection
  • Glecaprevir/pibrentasvir combination does not interact with HIV medications
  • Hepatitis A outbreak in Europe
  • Hepatitis C community summit, 18 & 19 April, Amsterdam
  • Is this your copy of the infohep news bulletin?

February 2017

  • HCV treatment as prevention
  • Progress towards HCV elimination
  • Guidelines on HCV and HBV testing
  • Effects of hepatitis C cure on extrahepatic disease in people with HIV/HCV co-infection
  • Lonafarnib for hepatitis delta
  • Is this your copy of the infohep news bulletin?

January 2017

  • Hep-CORE
  • Direct-acting antiviral treatment and kidney disease
  • Liver transplant demand
  • Liver cancer treatment
  • Vemlidy for hepatitis B approved in European Union
  • Counterfeit Harvoni found in Japan
  • Is this your copy of the infohep news bulletin?